Yarrow Bioscience prices 5,769,231-share follow-on at USD 26, raising USD 150 million
YARW•Offering terms
Yarrow Bioscience priced an underwritten public offering of 5,769,231 common shares at USD 26 per share.
Gross proceeds are expected to be about USD 150 million, before underwriting discounts, commissions, advisory fees, and other offering expenses.
The deal is expected to close Sept. 14, 2026, subject to customary closing conditions.
Underwriters have a 30-day option to buy up to 865,384 additional shares at the offering price.
Use of proceeds
Net proceeds are earmarked for R&D spending across the pipeline, working capital, capital expenditures, and general corporate purposes.
